Shares of Natus Medical Incorporated (NASDAQ:BABY) dropped 0.4% on Wednesday following insider selling activity. The stock traded as low as $38.30 and last traded at $40.85. Approximately 500,700 shares were traded during trading, an increase of 29% from the average daily volume of 386,740 shares. The stock had previously closed at $41.00.
Specifically, Director Robert A. Gunst sold 4,400 shares of Natus Medical stock in a transaction dated Thursday, September 14th. The stock was sold at an average price of $35.17, for a total value of $154,748.00. Following the transaction, the director now owns 50,850 shares in the company, valued at $1,788,394.50. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Also, VP Dong Chune Christopher Chung sold 12,642 shares of Natus Medical stock in a transaction dated Monday, November 6th. The shares were sold at an average price of $42.91, for a total value of $542,468.22. Following the completion of the transaction, the vice president now owns 141,414 shares in the company, valued at approximately $6,068,074.74. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 22,042 shares of company stock worth $902,266. Insiders own 5.50% of the company’s stock.
Several equities analysts have issued reports on BABY shares. Zacks Investment Research upgraded Natus Medical from a “hold” rating to a “buy” rating and set a $45.00 target price on the stock in a research note on Tuesday, October 24th. BidaskClub lowered Natus Medical from a “hold” rating to a “sell” rating in a research note on Tuesday, August 1st. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and two have assigned a buy rating to the company. The company has an average rating of “Hold” and a consensus target price of $46.50.
The company has a current ratio of 4.21, a quick ratio of 3.36 and a debt-to-equity ratio of 0.36. The company has a market cap of $1,277.32, a P/E ratio of 26.45 and a beta of 0.89.
Natus Medical (NASDAQ:BABY) last issued its quarterly earnings results on Wednesday, October 25th. The medical equipment provider reported $0.40 earnings per share for the quarter, topping the consensus estimate of $0.38 by $0.02. The business had revenue of $122.60 million during the quarter, compared to the consensus estimate of $122.41 million. Natus Medical had a positive return on equity of 12.06% and a negative net margin of 0.62%. The company’s quarterly revenue was up 34.9% on a year-over-year basis. During the same quarter last year, the company earned $0.39 earnings per share. equities research analysts forecast that Natus Medical Incorporated will post 1.74 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the business. Benjamin F. Edwards & Company Inc. boosted its holdings in Natus Medical by 2,085.6% in the third quarter. Benjamin F. Edwards & Company Inc. now owns 2,732 shares of the medical equipment provider’s stock worth $102,000 after acquiring an additional 2,607 shares in the last quarter. Riverhead Capital Management LLC boosted its holdings in Natus Medical by 90.9% in the second quarter. Riverhead Capital Management LLC now owns 2,864 shares of the medical equipment provider’s stock worth $107,000 after acquiring an additional 1,364 shares in the last quarter. Sei Investments Co. boosted its holdings in Natus Medical by 29.7% in the second quarter. Sei Investments Co. now owns 3,182 shares of the medical equipment provider’s stock worth $119,000 after acquiring an additional 728 shares in the last quarter. SG Americas Securities LLC acquired a new stake in Natus Medical in the third quarter worth about $138,000. Finally, Victory Capital Management Inc. boosted its holdings in Natus Medical by 17.6% in the second quarter. Victory Capital Management Inc. now owns 3,744 shares of the medical equipment provider’s stock worth $140,000 after acquiring an additional 560 shares in the last quarter. 99.53% of the stock is owned by institutional investors and hedge funds.
ILLEGAL ACTIVITY WARNING: “Natus Medical Incorporated (BABY) Trading Down 0.4% Following Insider Selling” was reported by StockNewsTimes and is owned by of StockNewsTimes. If you are accessing this report on another publication, it was copied illegally and republished in violation of U.S. & international copyright and trademark law. The original version of this report can be read at https://stocknewstimes.com/2017/11/15/natus-medical-incorporated-baby-trading-down-0-4-following-insider-selling.html.
About Natus Medical
Natus Medical Incorporated is a provider of newborn care and neurology healthcare products and services used for the screening, diagnosis, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, epilepsy, sleep disorders, neuromuscular diseases and balance and mobility disorders.
Receive News & Ratings for Natus Medical Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Natus Medical Incorporated and related companies with MarketBeat.com's FREE daily email newsletter.